Highly selective, high affinity MET inhibitor (Ki
= 6-7 nM against wild type c-Met). Displays >1000-fold selectivity for c-Met over a panel of 208 kinases.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold for research purposes under agreement from Pfizer Inc.
Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.
Eder et al.
Clin.Cancer Res., 2009;15:2207
Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors.
Timofeevski et al.
Discovery of small molecule c-Met inhibitors: evolution and profiles of clinical candidates.
Underiner et al.
Anticancer Agents Med.Chem., 2010;10:7
Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-
Cui et al.
The citations listed below are publications that use Tocris products. Selected citations for PF 04217903 mesylate include:
Showing Results 1 - 1 of 1